DK1229040T3 - Nukleosid-monophosphatderivater, en fremgangsmåde til fremstilling deraf og anvendelse deraf som immunosuppressive lægemidler - Google Patents

Nukleosid-monophosphatderivater, en fremgangsmåde til fremstilling deraf og anvendelse deraf som immunosuppressive lægemidler

Info

Publication number: DK1229040T3
Authority: DK; Denmark
Prior art keywords: desoxy; preparation; chain; nucleoside monophosphate; monophosphate derivatives
Prior art date: 1994-05-28

Application number

DK02008360T

Other languages

English (en)

Inventor

Dieter Herrmann

Harald Zilch

Alfred Mertens

Original Assignee

Heidelberg Pharma Holding Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-05-28

Filing date

1995-05-23

Publication date

2003-12-22

1995-05-23 Application filed by Heidelberg Pharma Holding Gmbh filed Critical Heidelberg Pharma Holding Gmbh

2003-12-22 Application granted granted Critical

2003-12-22 Publication of DK1229040T3 publication Critical patent/DK1229040T3/da

Links

-1 Nucleoside monophosphate Chemical class 0.000 title abstract 2
239000002777 nucleoside Substances 0.000 title abstract 2
239000003018 immunosuppressive agent Substances 0.000 title 1
229940124589 immunosuppressive drug Drugs 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 2
125000004432 carbon atom Chemical group C* 0.000 abstract 2
229920006395 saturated elastomer Polymers 0.000 abstract 2
AYWFLOPQIYDGTP-RJDJZVBFSA-N (2R,3S,4R,5R)-4-amino-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol 4-amino-1-[(2R,3R,4S,5R)-3-azido-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one (2R,3S,5R)-5-(6-amino-2-fluoropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol (2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-azido-2-(hydroxymethyl)oxolan-3-ol 5-fluoro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound FC=1N=C(C=2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2N1)N.FC=1C(NC(N([C@H]2C[C@H](O)[C@@H](CO)O2)C1)=O)=O.N(=[N+]=[N-])[C@H]1[C@@H](O[C@@H]([C@H]1O)CO)N1C(=O)N=C(N)C=C1.N(=[N+]=[N-])[C@H]1[C@@H](O[C@@H]([C@H]1O)CO)N1C=NC=2C(N)=NC=NC12.N[C@H]1[C@@H](O[C@@H]([C@H]1O)CO)N1C=NC=2C(N)=NC=NC12 AYWFLOPQIYDGTP-RJDJZVBFSA-N 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
150000007522 mineralic acids Chemical class 0.000 abstract 1
150000007524 organic acids Chemical class 0.000 abstract 1
235000005985 organic acids Nutrition 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
239000011593 sulfur Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Hematology (AREA)
Transplantation (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

DK02008360T 1994-05-28 1995-05-23 Nukleosid-monophosphatderivater, en fremgangsmåde til fremstilling deraf og anvendelse deraf som immunosuppressive lægemidler DK1229040T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4418690A DE4418690A1 (de)	1994-05-28	1994-05-28	Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel

Publications (1)

Publication Number	Publication Date
DK1229040T3 true DK1229040T3 (da)	2003-12-22

Family

ID=6519215

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK95920864T DK0763049T3 (da)	1994-05-28	1995-05-23	Nukleosid-monophosphatderivater, fremgangsmåde til fremstilling heraf og anvendelse heraf som immunundertrykkende lægemidler
DK02008360T DK1229040T3 (da)	1994-05-28	1995-05-23	Nukleosid-monophosphatderivater, en fremgangsmåde til fremstilling deraf og anvendelse deraf som immunosuppressive lægemidler

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK95920864T DK0763049T3 (da)	1994-05-28	1995-05-23	Nukleosid-monophosphatderivater, fremgangsmåde til fremstilling heraf og anvendelse heraf som immunundertrykkende lægemidler

Country Status (27)

Country	Link
US (1)	US6025343A (da)
EP (2)	EP1229040B8 (da)
JP (1)	JP3802057B2 (da)
KR (1)	KR100279087B1 (da)
CN (1)	CN1168735C (da)
AT (2)	ATE249472T1 (da)
AU (1)	AU688516B2 (da)
BR (1)	BR9507785A (da)
CA (1)	CA2190983C (da)
CZ (1)	CZ291846B6 (da)
DE (3)	DE4418690A1 (da)
DK (2)	DK0763049T3 (da)
ES (2)	ES2199250T3 (da)
FI (1)	FI117673B (da)
HU (1)	HU220336B (da)
IL (1)	IL113865A (da)
MX (1)	MX9605809A (da)
NO (1)	NO308998B1 (da)
NZ (1)	NZ287434A (da)
PL (1)	PL185290B1 (da)
PT (2)	PT1229040E (da)
RU (1)	RU2165429C2 (da)
SK (1)	SK284207B6 (da)
TW (1)	TW420686B (da)
UA (1)	UA45339C2 (da)
WO (1)	WO1995032984A1 (da)
ZA (1)	ZA954374B (da)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6458772B1 (en)	1909-10-07	2002-10-01	Medivir Ab	Prodrugs
JP3839857B2 (ja) *	1994-09-20	2006-11-01	塩野義製薬株式会社	エーテル型チオリン脂質化合物の製造方法
NZ297100A (en) *	1994-12-13	1997-10-24	Akira Matsuda	3'-substituted nucleoside derivatives; medicaments
WO1999051613A1 (en) *	1998-04-03	1999-10-14	Medivir Ab	Prodrugs of phosphorous-containing pharmaceuticals
US6407077B1 (en)	1998-11-05	2002-06-18	Emory University	β-L nucleosides for the treatment of HIV infection
WO2000026225A2 (en)	1998-11-05	2000-05-11	Centre National De La Recherche Scientifique	Nucleosides with anti-hepatitis b virus activity
DE19855963A1 (de) *	1998-12-04	2000-06-08	Herbert Schott	Amphiphile Glycerylnucleotide, Verfahren zu ihrer Herstellung und ihre Verwendung
US7026469B2 (en)	2000-10-19	2006-04-11	Wake Forest University School Of Medicine	Compositions and methods of double-targeting virus infections and cancer cells
US6620796B1 (en)	1999-11-08	2003-09-16	Micrologix Biotech Inc.	Combinatorial library synthesis and pharmaceutically active compounds produced thereby
US6787526B1 (en)	2000-05-26	2004-09-07	Idenix Pharmaceuticals, Inc.	Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US6875751B2 (en)	2000-06-15	2005-04-05	Idenix Pharmaceuticals, Inc.	3′-prodrugs of 2′-deoxy-β-L-nucleosides
WO2002057498A1 (en) *	2001-01-22	2002-07-25	Emergen, Inc.	Isotopically enriched nucleic acids and associated methods for the production and purification thereof
WO2002092006A2 (en)	2001-05-16	2002-11-21	Micrologix Biotech, Inc.	Nucleic acid-based compounds and methods of use thereof
CN1615314A (zh) *	2001-11-21	2005-05-11	海德堡医药有限责任公司	用作抗肿瘤药的核苷的磷脂衍生物
EP1831225A2 (en)	2004-11-19	2007-09-12	The Regents of the University of California	Anti-inflammatory pyrazolopyrimidines
RU2322450C2 (ru) *	2004-11-25	2008-04-20	Закрытое акционерное общество "Производственно-коммерческая Ассоциация АЗТ"	Модифицированные 5'-фосфонаты азт в качестве активных компонентов для потенциальных противовирусных препаратов
ES2401285T3 (es) *	2004-12-16	2013-04-18	The Regents Of The University Of California	Fármacos con el pulmón como diana
ES2325088T3 (es)	2004-12-30	2009-08-25	Medivir Ab	Compuestos utiles en el tratamiento de hiv.
GB0505781D0 (en) *	2005-03-21	2005-04-27	Univ Cardiff	Chemical compounds
CA2615980A1 (en) *	2005-07-22	2007-01-25	Giuliani International Limited	Improvements to analogous compounds of 6-thioguanosine triphosphate, their use in medical fields and processes for their preparation
ITRM20050391A1 (it) *	2005-07-22	2007-01-23	Giuliani Spa	Composti analoghi della 6-tioguanosina trifosfato, loro uso in campo medico e procedimento per la loro preparazione.
WO2007114926A2 (en)	2006-04-04	2007-10-11	The Regents Of The University Of California	Kinase antagonists
GB0608876D0 (en)	2006-05-05	2006-06-14	Medivir Ab	Combination therapy
US7378401B2 (en) *	2006-07-14	2008-05-27	Heidelberg Pharma Gmbh	Use of Fosfluridine Tidoxil (FT) for the treatment of intraepithelial proliferative diseases
US9296776B2 (en)	2007-07-09	2016-03-29	Eastern Virginia Medical School	Substituted nucleoside derivatives with antiviral and antimicrobial properties
GB2467670B (en)	2007-10-04	2012-08-01	Intellikine Inc	Chemical entities and therapeutic uses thereof
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2010007419A (es)	2008-01-04	2010-11-12	Intellikine Inc	Ciertas entidades quimicas, composiciones y metodos.
EP2252293B1 (en)	2008-03-14	2018-06-27	Intellikine, LLC	Kinase inhibitors and methods of use
US8993580B2 (en)	2008-03-14	2015-03-31	Intellikine Llc	Benzothiazole kinase inhibitors and methods of use
US20110224223A1 (en)	2008-07-08	2011-09-15	The Regents Of The University Of California, A California Corporation	MTOR Modulators and Uses Thereof
BRPI0915231A2 (pt)	2008-07-08	2018-06-12	Intellikine Inc	compostos inibidores de quinase e métodos de uso
CA2738429C (en)	2008-09-26	2016-10-25	Intellikine, Inc.	Heterocyclic kinase inhibitors
EP2358720B1 (en)	2008-10-16	2016-03-02	The Regents of The University of California	Fused ring heteroaryl kinase inhibitors
US8476431B2 (en)	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
JP5789252B2 (ja)	2009-05-07	2015-10-07	インテリカイン，エルエルシー	複素環式化合物およびその使用
WO2011047384A2 (en)	2009-10-16	2011-04-21	The Regents Of The University Of California	Methods of inhibiting ire1
CA2799579A1 (en)	2010-05-21	2011-11-24	Intellikine, Inc.	Chemical compounds, compositions and methods for kinase modulation
JP2013545749A (ja)	2010-11-10	2013-12-26	インフィニティーファーマシューティカルズ，インコーポレイテッド	複素環化合物及びその使用
ES2637113T3 (es)	2011-01-10	2017-10-10	Infinity Pharmaceuticals, Inc.	Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
US9295673B2 (en)	2011-02-23	2016-03-29	Intellikine Llc	Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
HK1198443A1 (en)	2011-07-19	2015-04-24	无限药品股份有限公司	Heterocyclic compounds and uses thereof
AR088218A1 (es)	2011-07-19	2014-05-21	Infinity Pharmaceuticals Inc	Compuestos heterociclicos utiles como inhibidores de pi3k
MX2014002542A (es)	2011-08-29	2014-07-09	Infinity Pharmaceuticals Inc	Compuestos heterociclicos y usos de los mismos.
CA2846496C (en)	2011-09-02	2020-07-14	The Regents Of The University Of California	Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
JP2015532287A (ja)	2012-09-26	2015-11-09	ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア	Ｉｒｅ１の調節
AU2013337717B2 (en)	2012-11-01	2018-10-25	Infinity Pharmaceuticals, Inc.	Treatment of cancers using PI3 kinase isoform modulators
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
SG10201800188SA (en)	2013-03-15	2018-02-27	Univ California	Acyclic nucleoside phosphonate diesters
PT3052485T (pt)	2013-10-04	2021-10-22	Infinity Pharmaceuticals Inc	Compostos heterocíclicos e suas utilizações
US9751888B2 (en)	2013-10-04	2017-09-05	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
MX382033B (es)	2014-03-19	2025-03-13	Infinity Pharmaceuticals Inc	Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
WO2015160975A2 (en)	2014-04-16	2015-10-22	Infinity Pharmaceuticals, Inc.	Combination therapies
DE102014112055A1 (de) *	2014-08-22	2016-02-25	Universität Hamburg	Di- und Triphosphat-Propharmaka
CN111808136B (zh)	2014-09-15	2024-06-11	加利福尼亚大学董事会	核苷酸类似物
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2017048702A1 (en)	2015-09-14	2017-03-23	Infinity Pharmaceuticals, Inc.	Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
EP3350191B9 (en)	2015-09-15	2021-12-22	The Regents of the University of California	Nucleotide analogs
WO2017161116A1 (en)	2016-03-17	2017-09-21	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
SG11201811237WA (en)	2016-06-24	2019-01-30	Infinity Pharmaceuticals Inc	Combination therapies
KR20250052378A (ko)	2022-07-21	2025-04-18	안티바 바이오사이언시즈, 인크.	Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태
AU2024352221A1 (en) *	2023-09-26	2026-04-09	Board Of Regents Of The University Of Nebraska	Phosphonate prodrugs and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2930904A1 (de) *	1979-07-30	1981-02-19	Kailash Kumar Dr Gauri	Verwendung von 5-alkyl-pyrimidinnucleosiden bei der bekaempfung von krebs
DE3476770D1 (en) *	1983-04-11	1989-03-23	Meito Sangyo Kk	Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique
GB2175588B (en) *	1985-04-15	1988-08-10	Toyo Jozo Kk	Nucleoside-phospholipid conjugates
DE3778626D1 (de) *	1986-09-27	1992-06-04	Toyo Jozo Kk	Nukleosid-phospholipid-konjugat.
JP2796089B2 (ja) *	1986-10-06	1998-09-10	旭化成工業株式会社	リン脂質誘導体の製造法
DE3730542A1 (de) *	1987-09-11	1989-04-06	Hoechst Ag	Arzneimittel mit einem gehalt an bestimmten 6-mercaptopurin-derivaten, verwendung dieser 6-mercaptopurin-derivate, verfahren zur herstellung der arzneimittel sowie einige neue 6-mercaptopurin-derivate und verfahren zu deren herstellung
US5463092A (en) *	1989-11-22	1995-10-31	Vestar, Inc.	Lipid derivatives of phosphonacids for liposomal incorporation and method of use
DE4026265A1 (de) *	1990-08-20	1992-02-27	Boehringer Mannheim Gmbh	Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
US5563257A (en) *	1990-08-20	1996-10-08	Boehringer Mannheim Gmbh	Phospholipid derivatives of nucleosides
DE4111730A1 (de) *	1991-04-10	1992-10-15	Knoll Ag	Neue cytarabin-derivate, ihre herstellung und verwendung
AU668873B2 (en) *	1991-07-12	1996-05-23	Chimerix, Inc.	Antiviral liponucleosides: treatment of hepatitis B
DE4204032A1 (de) *	1992-02-12	1993-08-19	Boehringer Mannheim Gmbh	Neue liponucleotide, deren herstellunmg sowie deren verwendung als antivirale arzneimittel
US5512671A (en) *	1993-02-16	1996-04-30	Wake Forest University	Ether lipid-nucleoside covalent conjugates

1994
- 1994-05-28 DE DE4418690A patent/DE4418690A1/de not_active Withdrawn
1995
- 1995-05-23 CN CNB951943715A patent/CN1168735C/zh not_active Expired - Fee Related
- 1995-05-23 SK SK1518-96A patent/SK284207B6/sk not_active IP Right Cessation
- 1995-05-23 PT PT02008360T patent/PT1229040E/pt unknown
- 1995-05-23 ES ES95920864T patent/ES2199250T3/es not_active Expired - Lifetime
- 1995-05-23 AT AT02008360T patent/ATE249472T1/de not_active IP Right Cessation
- 1995-05-23 WO PCT/EP1995/001951 patent/WO1995032984A1/en not_active Ceased
- 1995-05-23 PT PT95920864T patent/PT763049E/pt unknown
- 1995-05-23 DK DK95920864T patent/DK0763049T3/da active
- 1995-05-23 RU RU96124383/04A patent/RU2165429C2/ru active
- 1995-05-23 JP JP50026296A patent/JP3802057B2/ja not_active Expired - Fee Related
- 1995-05-23 DE DE69531749T patent/DE69531749T2/de not_active Expired - Fee Related
- 1995-05-23 BR BR9507785A patent/BR9507785A/pt not_active Application Discontinuation
- 1995-05-23 EP EP02008360A patent/EP1229040B8/en not_active Expired - Lifetime
- 1995-05-23 NZ NZ287434A patent/NZ287434A/en not_active IP Right Cessation
- 1995-05-23 ES ES02008360T patent/ES2206429T3/es not_active Expired - Lifetime
- 1995-05-23 CA CA002190983A patent/CA2190983C/en not_active Expired - Fee Related
- 1995-05-23 DK DK02008360T patent/DK1229040T3/da active
- 1995-05-23 HU HU9603269A patent/HU220336B/hu not_active IP Right Cessation
- 1995-05-23 UA UA96114469A patent/UA45339C2/uk unknown
- 1995-05-23 MX MX9605809A patent/MX9605809A/es not_active IP Right Cessation
- 1995-05-23 AU AU26154/95A patent/AU688516B2/en not_active Ceased
- 1995-05-23 KR KR1019960706690A patent/KR100279087B1/ko not_active Expired - Fee Related
- 1995-05-23 CZ CZ19963477A patent/CZ291846B6/cs not_active IP Right Cessation
- 1995-05-23 AT AT95920864T patent/ATE236189T1/de not_active IP Right Cessation
- 1995-05-23 EP EP95920864A patent/EP0763049B1/en not_active Expired - Lifetime
- 1995-05-23 DE DE69530197T patent/DE69530197T2/de not_active Expired - Fee Related
- 1995-05-24 TW TW084105233A patent/TW420686B/zh active
- 1995-05-25 IL IL113865A patent/IL113865A/en not_active IP Right Cessation
- 1995-05-29 ZA ZA954374A patent/ZA954374B/xx unknown
1996
- 1996-11-21 PL PL95317380A patent/PL185290B1/pl not_active IP Right Cessation
- 1996-11-27 US US08/753,633 patent/US6025343A/en not_active Expired - Fee Related
- 1996-11-27 FI FI964727A patent/FI117673B/fi active IP Right Grant
- 1996-11-27 NO NO965054A patent/NO308998B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
FI117673B (fi)	2007-01-15
EP1229040B1 (en)	2003-09-10
MX9605809A (es)	1997-12-31
CA2190983A1 (en)	1995-12-07
UA45339C2 (uk)	2002-04-15
HUT75340A (en)	1997-05-28
FI964727L (fi)	1996-11-27
ZA954374B (en)	1996-11-29
HU9603269D0 (en)	1997-01-28
DE4418690A1 (de)	1996-01-11
EP0763049A1 (en)	1997-03-19
PL185290B1 (pl)	2003-04-30
CN1168735C (zh)	2004-09-29
SK284207B6 (en)	2004-11-03
DE69531749T2 (de)	2004-07-29
JP3802057B2 (ja)	2006-07-26
EP1229040A3 (en)	2002-08-21
IL113865A (en)	2008-12-29
DE69531749D1 (de)	2003-10-16
ES2206429T3 (es)	2004-05-16
IL113865A0 (en)	1995-08-31
PL317380A1 (en)	1997-04-01
EP0763049B1 (en)	2003-04-02
DE69530197D1 (de)	2003-05-08
PT763049E (pt)	2003-08-29
HU220336B (hu)	2001-12-28
TW420686B (en)	2001-02-01
NO965054D0 (no)	1996-11-27
NZ287434A (en)	1998-01-26
EP1229040A2 (en)	2002-08-07
NO308998B1 (no)	2000-11-27
AU688516B2 (en)	1998-03-12
CN1154111A (zh)	1997-07-09
DK0763049T3 (da)	2003-07-28
RU2165429C2 (ru)	2001-04-20
WO1995032984A8 (en)	2003-01-16
CZ291846B6 (cs)	2003-06-18
KR100279087B1 (ko)	2001-01-15
KR970703354A (ko)	1997-07-03
JPH10500964A (ja)	1998-01-27
ATE249472T1 (de)	2003-09-15
ES2199250T3 (es)	2004-02-16
PT1229040E (pt)	2003-12-31
US6025343A (en)	2000-02-15
BR9507785A (pt)	1997-09-23
CZ347796A3 (en)	1997-04-16
WO1995032984A1 (en)	1995-12-07
ATE236189T1 (de)	2003-04-15
DE69530197T2 (de)	2004-01-29
AU2615495A (en)	1995-12-21
SK151896A3 (en)	1997-06-04
NO965054L (no)	1997-01-28
EP1229040B8 (en)	2003-11-05
FI964727A0 (fi)	1996-11-27
CA2190983C (en)	2006-08-15

Publication	Publication Date	Title
DK1229040T3 (da)	2003-12-22	Nukleosid-monophosphatderivater, en fremgangsmåde til fremstilling deraf og anvendelse deraf som immunosuppressive lægemidler
ES514240A0 (es)	1984-04-16	Un procedimiento para la prepracion de nuevos derivados de acidos 2-carbamimidoil-1-,carbadestiapen-2-en-3-carboxilados.
PT93552A (pt)	1990-11-07	Processo para a preparacao de derivados de pirrol acriloil-substituidos e de composicoes farmaceuticas que os contem
ES2058670T3 (es)	1994-11-01	Derivados amidicos y preparados dermatologicos que los contienen.
TW343975B (en)	1998-11-01	New phospholipid derivatives of phosphonocarboxylic acids, the production thereof as well as their use as antiviral pharmaceutical agents
OA08420A (fr)	1988-06-30	Nouveaux dérivés d'alkylmercaptophényl-1,3,4-oxadiazole ou -1,3,4-tiadiazole substitués, leur préparation, agents nématicides les contenant, procédé de préparation de ces agents et leur utilisation.
SE8700914D0 (sv)	1987-03-04	Anvendning av adenosinderivat
KR850008157A (ko)	1985-12-13	아미노산 및 이 에스테르의 n-아실유도체의 제조방법
ATE67506T1 (de)	1991-10-15	Pristinamycin-verfahren.
ATE198746T1 (de)	2001-02-15	Pyrimidinderivate und pharmazeutische zusammensetzungen
PT88462A (pt)	1988-10-01	Process for the preparation of macrolide compounds and of compositions containing them
DK0428132T3 (da)	1993-10-11	Pradimicinderivater
ATE115951T1 (de)	1995-01-15	Glycocyamidin-derivate.
DK0627419T3 (da)	2000-04-25	Optisk aktive derivater af 1-phenylpyrrolidon og fremgangsmåde til fremstilling deraf
IT1248558B (it)	1995-01-19	Derivati della fisovenina utili per il trattamento delle malattie associate a disordini colinergici, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.